| Literature DB >> 27350946 |
Marianna G Mavilia1, Marco Molina2, George Y Wu3.
Abstract
Hepatic abscess (HA) remains a serious and often difficult to diagnose problem. HAs can be divided into three main categories based on the underlying conditions: infectious, malignant, and iatrogenic. Infectious abscesses include those secondary to direct extension from local infection, systemic bacteremia, and intra-abdominal infections that seed the portal system. However, over the years, the etiologies and risks factors for HA have continued to evolve. Prompt recognition is important for instituting effective management and obtaining good outcomes.Entities:
Keywords: Iatrogenic disease; Liver abscess; Liver neoplasms; Risk factors
Year: 2016 PMID: 27350946 PMCID: PMC4913073 DOI: 10.14218/JCTH.2016.00004
Source DB: PubMed Journal: J Clin Transl Hepatol ISSN: 2225-0719
Risk factors for development of hepatic abscess (HA) and increased mortality from HA
| Increased risk of developing HA | Increased mortality from HA |
| Diabetes mellitus | Malignancy |
| Liver cirrhosis | Diabetes mellitus |
| Immune-compromised state | Liver cirrhosis |
| Use of PPI | Male gender |
| Advanced age | Multiorgan failure |
| Male gender | Sepsis |
| Infection with mixed organisms | |
| HA rupture | |
| Abscess size > 5 cm | |
| Respiratory distress | |
| Hypotension | |
| Jaundice | |
| Extrahepatic involvement |
Diabetes mellitus, liver cirrhosis and male gender are risk factors for both development and increased mortality of HA.
Fig. 1.The gray areas.
Fig. 1 depicts a comparison of the sub-groups of HA and also delineates the areas of overlap between them.
Fig. 2.Routes of infection.
Clinical findings
| Signs and symptoms | |
|---|---|
| Malaise | 89% |
| Chills | 69% |
| Fever | 59%–90% |
| Tachycardia | 52% |
| Nausea | 43%–68% |
| Abdominal pain | 39%–84% |
| Vomiting | 30%–32% |
| Right pleural effusion | 28% |
| Weight loss | 26% |
| Jaundice | 19%–21% |
| Ascites | 18%–21% |
| Murphy’s sign | 16% |
| Hepatomegaly | 16%–52% |
| Guarding | 14% |
| Respiratory distress | 13% |
| Hypotension | 13%–30% |
| Diarrhea | 11% |
| Anorexia | 11% |
Laboratory findings
| Abnormal laboratory finding | |
|---|---|
| C-reactive protein | 100% |
| Hemoglobin | 82% |
| Bilirubin | 75% |
| GGT | 75% |
| WBC | 74% |
| ALT | 73% |
| Albumin | 73% |
| ALP | 71% |
| AST | 67% |
| INR | 13% |
Adapted from Pang TC, Fung T, Samra J, Hugh TJ, Smith RC. Pyogenic liver abscess: an audit of 10 years’ experience. World J Gastroenterol 2011;17:1622-1630. doi:10.3748/wjg.v17.i12.1622.
Abbreviations: ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, alanine aminotransferase; GGT, gamma glutamyl transpeptidase; INR, international normalized ratio; WBC, white blood cell count.
Fig. 3.Ultrasound (US).
A. US demonstrates a hypoechoic abscess with heterogeneous echogenicity centrally consistent with septations and internal debris (blue arrow). B. Color Doppler US demonstrates peripheral hypervascularity surrounding the abscess cavity.
Fig. 4.Dynamic contrast-enhanced computed tomography (CT).
A. Late arterial phase CT demonstrates hypervascular, peripheral enhancement of the abscess seen in Figure 4 (blue arrow). B. Portal venous phase CT demonstrates conspicuity of internally enhancing septations (blue star), likely representing intervening hepatic parenchyma. Note the multilocular nature of the abscess, which has implications for potential treatments (blue arrows).
Fig. 5.Magnetic resonance imaging (MRI).
A. T2-weighted image demonstrates multiple (at least six) small hyperintense abscess cavities in the right hepatic lobe (blue arrows). Note the hyperintense, edematous hepatic parenchyma (blue star). B. Noncontrast T1-weighted fat-sat image demonstrates varying degrees of T1 hyperintensity in the abscess cavities consistent with proteinaceous debris. C. Postcontrast T1-weighted fat-sat image demonstrates peripheral or rim enhancement around each of the abscesses.
Treatment success rates
| Alkofer | 70% | 75.4% | 91.6% |
| Ferraioli | – | 95.4% | 93.2% |
| Hope | 100% | 83% | 100% |
| 33% | |||
| Tan | – | 72.2% | 93.8% |
| Bamberger | 81.2% | – | – |
Fig. 6.Treatment strategies of HA*.